286 related articles for article (PubMed ID: 22085387)
1. Current status of targeted therapies for mantle cell lymphoma.
Chang JE; Kahl BS
Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
[TBL] [Abstract][Full Text] [Related]
2. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
7. Novel agents in mantle cell lymphoma.
Kumar A
Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
[TBL] [Abstract][Full Text] [Related]
8. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeted approaches in mantle cell lymphoma.
Weniger MA; Wiestner A
Semin Hematol; 2011 Jul; 48(3):214-26. PubMed ID: 21782064
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
12. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Coiffier B
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma: the promise of new treatment options.
Goy A; Kahl B
Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
[TBL] [Abstract][Full Text] [Related]
17. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
[TBL] [Abstract][Full Text] [Related]
19. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma: evolving novel options.
Goy A
Curr Oncol Rep; 2007 Sep; 9(5):391-8. PubMed ID: 17706168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
